Several possible studies
Story checked
Streamlining CRISPR workflows, from editing to analysis (opens in a new tab)
news-medical.net · 2026-09-30
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Streamlining CRISPR workflows, from editing to analysis
news-medical.net · 2026-09-30
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The 2 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- Cited as backgroundpresented as earlier work
Miniaturized scalable arrayed CRISPR screening in primary cells enables discovery at the single donor resolution
Scientific Reports · 2025
- Cited as backgroundpresented as earlier work
A Tri‐Droplet Liquid Structure for Highly Efficient Intracellular Delivery in Primary Mammalian Cells Using Digital Microfluidics
Advanced Materials Technologies · 2023
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedCRISPR discovery and development workflows have two critical stages: gene editing and then confirming that the intended result has been achieved, and both steps can be slow and error-prone when done manually.View evidenceHide evidence
As stateddays or even weeks for analysis
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 6Not checkedDropGenie and INTEGRA collaborated to automate low-input electroporation, using the ASSIST PLUS liquid-handling robot and VOYAGER pipette to streamline CRISPR editing in scarce, sensitive cells.View evidenceHide evidence
As stated10,000 cells per edit versus about 1 million cells conventionally; 100x reduction
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 6Not checkedThe DropGenie platform combines digital microfluidics and tri-drop electroporation, with 48 independent programmable reaction sites, to enable efficient genome editing with reduced cellular input.View evidenceHide evidence
As stated48 reaction sites
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 6Not checkedThe article reports that DropGenie demonstrated efficient CRISPR knockouts with excellent recovery and viability, including TRAC knockout efficiency of 92.5% in CD4+ T-cells and 90.9% in CD8+ T-cells, with coefficients of variation below 5%.View evidenceHide evidence
As stated92.5%, 90.9%, below 5% CV
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 6Not checkedQUiCKR Bio offers a rapid assay and cloud analysis platform that can quantify DNA sequences with NGS-level accuracy in about 20 minutes and is used to confirm whether intended edits occurred.View evidenceHide evidence
As stated20 minutes
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 6Not checkedThe article says QUiCKR’s editing-efficiency measurements match NGS results with an r2 fit of 0.96 and that automation can reduce hands-on time by up to 75% in the workflow.View evidenceHide evidence
As stated0.96 r2 fit; up to 75% hands-on time reduction
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 40 candidate papers
Miniaturized scalable arrayed CRISPR screening in primary cells enables discovery at the single donor resolution
Scientific Reports · 2025 · PubMed, Europe PMC, Crossref
A Tri‐Droplet Liquid Structure for Highly Efficient Intracellular Delivery in Primary Mammalian Cells Using Digital Microfluidics
Advanced Materials Technologies · 2023 · Crossref
Correction: Miniaturized scalable arrayed CRISPR screening in primary cells enables discovery at the single donor resolution.
Scientific Reports · 2025 · PubMed
Male Sterility System in Vegetable Crops: Mechanism, Breeding Strategies and Applications
Journal of Scientific Research and Reports · 2025 · Crossref
Interventions to Improve Medication Adherence in People With Hypertension: Protocol for a Systematic Review and Meta-Analysis.
2025 · Europe PMC
And 35 more candidates considered.